This differs from other commonly expressed lung cancer mutations such as in ROS1 [26], anaplastic lymphoma kinase (ALK) [27], and the epidermal growth factor receptor (EGFR) [28] which have all seen significant success and acceleration with targeted therapy development in the last decade. This evidence concerns the gene EGFR and lung carcinoma.